AU1646201A - Pharmaceutical agent for the treatment of cachexia and/or cardiogenic shock - Google Patents
Pharmaceutical agent for the treatment of cachexia and/or cardiogenic shockInfo
- Publication number
- AU1646201A AU1646201A AU16462/01A AU1646201A AU1646201A AU 1646201 A AU1646201 A AU 1646201A AU 16462/01 A AU16462/01 A AU 16462/01A AU 1646201 A AU1646201 A AU 1646201A AU 1646201 A AU1646201 A AU 1646201A
- Authority
- AU
- Australia
- Prior art keywords
- cachexia
- treatment
- pharmaceutical agent
- cardiogenic shock
- cardiogenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19948126A DE19948126A1 (de) | 1999-10-06 | 1999-10-06 | Pharmazeutisches Mittel zur Behandlung von Kachexie und/oder kardiogenem Schock |
DE19948126 | 1999-10-06 | ||
PCT/DE2000/003481 WO2001024782A2 (de) | 1999-10-06 | 2000-10-04 | Pharmazeutisches mittel zur behandlung von kachexie und/oder kardiogenem schock |
Publications (1)
Publication Number | Publication Date |
---|---|
AU1646201A true AU1646201A (en) | 2001-05-10 |
Family
ID=7924678
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU16462/01A Abandoned AU1646201A (en) | 1999-10-06 | 2000-10-04 | Pharmaceutical agent for the treatment of cachexia and/or cardiogenic shock |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU1646201A (de) |
DE (1) | DE19948126A1 (de) |
WO (1) | WO2001024782A2 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6613083B2 (en) * | 2001-05-02 | 2003-09-02 | Eckhard Alt | Stent device and method |
JP2007501243A (ja) | 2003-08-04 | 2007-01-25 | ブリストル−マイヤーズ スクイブ カンパニー | 可溶性ctla4分子を用いる心臓血管疾患の治療方法 |
JP2008517584A (ja) * | 2004-08-16 | 2008-05-29 | アディポジェン ファーマシューティカルズ ピーティーワイ リミテッド | 代謝調節薬剤およびそのための使用 |
MX2009001857A (es) * | 2006-08-22 | 2009-03-02 | Novartis Ag | Tratamiento de trastornos fibrosantes. |
US9370508B2 (en) * | 2007-02-20 | 2016-06-21 | Novartis Ag | Imidazoquinolines as dual lipid kinase and mTOR inhibitors |
EP2883883A1 (de) * | 2013-12-16 | 2015-06-17 | Cardio3 Biosciences S.A. | Therapeutische Ziele und Mittel zur Behandlung von ischämiebedingten Reperfusionsschäden |
CN111905103A (zh) * | 2019-05-10 | 2020-11-10 | 深圳瑞健生命科学研究院有限公司 | 一种治疗肌萎缩侧索硬化的方法和药物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL92382A (en) * | 1988-11-23 | 1994-12-29 | Univ Michigan | Use of a ligand specific for CD28 in the manufacture of medicament |
US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
JPH10500669A (ja) * | 1994-04-12 | 1998-01-20 | アルザ・コーポレーション | サイトカイン阻害薬に関するスクリーニング法 |
RU2147442C1 (ru) * | 1994-10-21 | 2000-04-20 | Кисимото Тадамицу | Фармацевтическая композиция для профилактики или лечения заболеваний, вызываемых образованием il-6 |
JP3827350B2 (ja) * | 1994-10-21 | 2006-09-27 | 忠三 岸本 | Il−6産生に起因する疾患の治療剤 |
US6054559A (en) * | 1997-01-28 | 2000-04-25 | Smithkline Beecham Corporation | Interleukin-1 receptor antagonist beta (IL-1raβ) |
SK13642000A3 (sk) * | 1998-03-16 | 2001-04-09 | Celgene Corporation | 2-(2,6-dioxopiperidin-3-yl)izoindolínové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie |
AU766831B2 (en) * | 1998-05-11 | 2003-10-23 | Takeda Pharmaceutical Company Limited | Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity |
-
1999
- 1999-10-06 DE DE19948126A patent/DE19948126A1/de not_active Withdrawn
-
2000
- 2000-10-04 WO PCT/DE2000/003481 patent/WO2001024782A2/de active Application Filing
- 2000-10-04 AU AU16462/01A patent/AU1646201A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2001024782A2 (de) | 2001-04-12 |
DE19948126A1 (de) | 2001-04-12 |
WO2001024782A3 (de) | 2002-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU4205100A (en) | Methods and compositions for the treatment of pancreatitis | |
AU2003200740A1 (en) | Compositions and methods for the treatment of tumor | |
AU2003200731A1 (en) | Compositions and methods for the treatment of tumor | |
AU2003200722A1 (en) | Compositions and methods for the treatment of tumor | |
AU2495200A (en) | Compositions and methods for the treatment of tumor | |
MXPA02004770A (es) | Composiciones terapeuticas y metodos para su uso. | |
WO2000066104A3 (en) | Ace-2 inhibiting compounds and methods of use thereof | |
KR100510795B1 (en) | Compositions and Methods for the Treatment of Tumor | |
AU4136901A (en) | Novel methods for the treatment and prevention of dizziness and pruritus | |
AU1794801A (en) | Method for treatment and prevention of physiological shock | |
AU1646201A (en) | Pharmaceutical agent for the treatment of cachexia and/or cardiogenic shock | |
AU7601400A (en) | Treatment and prevention of hepatic disorders | |
AU4228000A (en) | Methods and compositions for the treatment and prevention of lung disease | |
HUP0105310A2 (en) | Use of phosphororganic compounds for the prophylactic and therapeutical treatment of infections | |
IL147410A0 (en) | L-acetylcarnitine and l-propionylcarnitine containing composition for the prevention and treatment of kidney dysfunctions and diseases | |
AU7653600A (en) | Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis | |
EP1143990A3 (de) | Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen | |
AU2566201A (en) | Compounds and methods for the treatment of pain | |
AU2420101A (en) | Method and composition for the treatment of pain | |
HU0001891D0 (en) | Medicament for the treatment of migraine | |
AU4225500A (en) | Methods and compositions for the treatment and prevention of lung disease | |
AU1392601A (en) | Prevention and treatment of biomaterial-associated infections | |
AU3735900A (en) | Methods of treatment and prevention of restenosis | |
IL143795A0 (en) | Use of 3-isoxazolidinones and hydroxylamic acids for the treatment of infections | |
AU1792200A (en) | Use of phanquinone for the treatment or prevention of memory impairment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase | ||
TH | Corrigenda |
Free format text: IN VOL 15, NO 31, PAGE(S) 6600-6603 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO APPLICATION NO. 75452/00, 76732/00, 76913/00, 77683/00, 77845/00, 10631/01, 13812/01, 16462/01, 19920/01 AND 21479/01 |
|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |